Heron Therapeutics, Inc. – LSE:0J4V.L
Heron Therapeutics stock price today
Heron Therapeutics stock price monthly change
Heron Therapeutics stock price quarterly change
Heron Therapeutics stock price yearly change
Heron Therapeutics key metrics
Market Cap | 233.99M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -0.61 |
Revenue | 132.09M |
EBITDA | -79.48M |
Income | -80.95M |
Revenue Q/Q | 17.06% |
Revenue Y/Y | 16.04% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | -60.17% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeHeron Therapeutics stock price history
Heron Therapeutics stock forecast
Heron Therapeutics financial statements
| Jun 2023 | 31.76M | -42.05M | -132.42% |
|---|---|---|---|
| Sep 2023 | 31.43M | -25.00M | -79.56% |
| Dec 2023 | 34.23M | -10.72M | -31.33% |
| Mar 2024 | 34.67M | -3.16M | -9.11% |
| 2025 | 173.38M | -1.95M | -1.13% |
|---|---|---|---|
| 2026 | 205.22M | 20.86M | 10.17% |
| 2027 | 244.4M | 45.58M | 18.65% |
| 2028 | 288.76M | 62.85M | 21.77% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 201224000 | 240.50M | 119.52% |
|---|---|---|---|
| Sep 2023 | 229199000 | 256.98M | 112.12% |
| Dec 2023 | 222506000 | 256.47M | 115.27% |
| Mar 2024 | 217887000 | 251.65M | 115.5% |
| Jun 2023 | -27.16M | 13.21M | 319K |
|---|---|---|---|
| Sep 2023 | -9.17M | -23.22M | 53.79M |
| Dec 2023 | 2.45M | -8.83M | 199K |
| Mar 2024 | -9.51M | 1.27M | 11K |
Heron Therapeutics alternative data
| Aug 2023 | 203 |
|---|---|
| Sep 2023 | 203 |
| Oct 2023 | 203 |
| Nov 2023 | 203 |
| Dec 2023 | 203 |
| Jan 2024 | 203 |
| Feb 2024 | 203 |
| Mar 2024 | 126 |
| Apr 2024 | 126 |
| May 2024 | 126 |
| Jun 2024 | 126 |
| Jul 2024 | 126 |
Heron Therapeutics other data
| Patent |
|---|
Grant Filling date: 17 Jul 2019 Issue date: 22 Feb 2022 |
Grant Filling date: 16 Mar 2020 Issue date: 16 Nov 2021 |
Application Filling date: 14 Dec 2020 Issue date: 4 Nov 2021 |
Application Filling date: 9 Jul 2021 Issue date: 28 Oct 2021 |
Application METHODS OF TREATING NAUSEA UTILIZING SEMI-SOLID DELIVERY VEHICLE COMPOSITIONS COMPRISING GRANISETRON Filling date: 26 Apr 2021 Issue date: 19 Aug 2021 |
Grant Filling date: 12 Sep 2017 Issue date: 10 Aug 2021 |
Grant Filling date: 21 Oct 2016 Issue date: 10 Aug 2021 |
Application Filling date: 21 Dec 2020 Issue date: 22 Jul 2021 |
Application Filling date: 22 Mar 2021 Issue date: 8 Jul 2021 |
Application Filling date: 5 Mar 2021 Issue date: 24 Jun 2021 |
| Insider | Compensation |
|---|---|
| Dr. Barry D. Quart (1957) Chairman & Chief Executive Officer | $954,110 |
Ms. Kimberly J. Manhard (1960) Executive Vice President of Drug Devel. & Director | $694,590 |
Mr. John W. Poyhonen (1960) Pres & Chief Commercial Officer | $421,250 |
| Ms. Lisa Peraza Vice President & Chief Accounting Officer | |
Mr. Michael E. Mathews Senior Vice President of Pain Franchise | |
Dr. Thomas B. Ottoboni Chief Scientific Officer and Senior Vice President of Pharmaceutical & Translational Sciences | |
Mr. David L. Szekeres Executive Vice President & Chief Operating Officer | |
Dr. Chris M. Storgard Chief Medical Officer | |
Mr. Sean T. Ristine Vice President of HR |
-
What's the price of Heron Therapeutics stock today?
One share of Heron Therapeutics stock can currently be purchased for approximately $31.3.
-
When is Heron Therapeutics's next earnings date?
Unfortunately, Heron Therapeutics's (0J4V.L) next earnings date is currently unknown.
-
Does Heron Therapeutics pay dividends?
No, Heron Therapeutics does not pay dividends.
-
How much money does Heron Therapeutics make?
Heron Therapeutics has a market capitalization of 233.99M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 17.99% to 127.04M US dollars.
-
What is Heron Therapeutics's stock symbol?
Heron Therapeutics, Inc. is traded on the LSE under the ticker symbol "0J4V.L".
-
What is Heron Therapeutics's primary industry?
Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.
-
How do i buy shares of Heron Therapeutics?
Shares of Heron Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Heron Therapeutics's key executives?
Heron Therapeutics's management team includes the following people:
- Dr. Barry D. Quart Chairman & Chief Executive Officer(age: 68, pay: $954,110)
- Ms. Kimberly J. Manhard Executive Vice President of Drug Devel. & Director(age: 65, pay: $694,590)
- Mr. John W. Poyhonen Pres & Chief Commercial Officer(age: 65, pay: $421,250)
- Ms. Lisa Peraza Vice President & Chief Accounting Officer
- Mr. Michael E. Mathews Senior Vice President of Pain Franchise
- Dr. Thomas B. Ottoboni Chief Scientific Officer and Senior Vice President of Pharmaceutical & Translational Sciences
- Mr. David L. Szekeres Executive Vice President & Chief Operating Officer
- Dr. Chris M. Storgard Chief Medical Officer
- Mr. Sean T. Ristine Vice President of HR
-
How many employees does Heron Therapeutics have?
As Jul 2024, Heron Therapeutics employs 126 workers.
-
When Heron Therapeutics went public?
Heron Therapeutics, Inc. is publicly traded company for more then 7 years since IPO on 29 Jan 2018.
-
What is Heron Therapeutics's official website?
The official website for Heron Therapeutics is herontx.com.
-
Where are Heron Therapeutics's headquarters?
Heron Therapeutics is headquartered at 4242 Campus Point Court, San Diego, CA.
-
How can i contact Heron Therapeutics?
Heron Therapeutics's mailing address is 4242 Campus Point Court, San Diego, CA and company can be reached via phone at 858 251 4400.
Heron Therapeutics company profile:
Heron Therapeutics, Inc.
herontx.comLSE
126
Medical - Pharmaceuticals
Healthcare
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
San Diego, CA 92121
:
ISIN: US4277461020
:
